IP Library Granted Patent US 10,016,415
Granted Patent B2
US 10,016,415 · App. 14/828,229 · Granted Jul 10, 2018

Aripiprazole prodrug compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,016,415
App. No.
14/828,229
Granted
Jul 10, 2018
Kind
B2
Abstract

Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilization of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.

Claims (17)

1. A composition consisting of polysorbate 20 and a population of particles of the formula:

having a volume based particle distribution size (Dv50) between about 350 nm and about 175 nm as determined by light scattering techniques, wherein the ratio of said particles to polysorbate 20 is 17:1.

2. A composition consisting of polysorbate 20, a chelating agent, a tonicity agent, an aqueous buffer, and a population of particles of the formula:

having a volume based particle distribution size (Dv50) between about 350 nm and about 175 nm as determined by light scattering techniques, wherein the ratio of the particles to polysorbate 20 is 17:1.

3. The composition of claim 2 , wherein the chelating agent is sodium citrate.

4. The composition of claim 2 , wherein the tonicity agent is sodium chloride.

5. A composition consisting of polysorbate 20, sodium citrate, sodium chloride, an aqueous buffer, and a population of particles of the formula:

having a volume based particle distribution size (Dv50) between about 350 nm and about 175 nm as determined by light scattering techniques, wherein the ratio of the particles to polysorbate 20 is 17:1.

6. A composition consisting of:

(a) about 26 weight percent of a compound of the following formula:

(b) 1.53 weight percent polysorbate 20;

(c) 0.76 weight percent sodium citrate;

(d) 0.31 weight percent sodium chloride; and

(e) an aqueous buffer,

wherein the compound is provided as a population of particles having a volume based particle distribution size (Dv50) between about 350 nm and about 175 nm as determined by light scattering techniques.

7. The composition of claim 6 , wherein the ratio of the particles to polysorbate 20 is 17:1.

8. The composition of claim 2 , wherein the composition is an aqueous dispersion.

Assignments (6)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
RELEASE OF PATENT SECURITY AGREEMENTS Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0701 →
SECURITY INTEREST Recorded Mar 20, 2020
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 052914/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2016
From: CRESSWELL, PHILIP; PAQUETTE, SARA MONTMINY; HICKEY, MAGALI; PERKIN, KRISTOPHER; SMITH, GREG; LIVERSIDGE, ELAINE; STEINBERG, BRIAN; MANSER, DAVID; TURNCLIFF, RYAN; PALMIERI, MICHAEL, JR.; ZEIDAN, TAREK; CASH, ETHAN P.; HARD, MARJIE L.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 037643/0833 →